Abstract
Cardiovascular disease (CVD) is a leading cause of death and hospitalization worldwide. The need for small caliber vessels (<6mm) to treat CVD patients has grown; however the availability of autologous vessels in cardiac and peripheral bypass candidates is limited. The search for an alternative vessel source is widespread with both natural and synthetic tissue engineered materials being investigated as scaffolds. Despite decades of exhaustive studies with decellularized extracellular matrices (ECM) and synthetic graft materials, the field remains in search of a commercially viable biomaterial construct substitute. While the previous materials have been assessed by evaluating their compatibility with fibroblasts, smooth muscle cells and endothelial cells, current materials are being conceived based on their interactions with stem cells, progenitor cells and monocytes, as the latter may hold the key to repair and regeneration. The graft’s ability to recruit and maintain these cells has become a major research focus. The successful tissue engineering of a small caliber vessel graft requires the use of optimal material chemistry and biological function to promote cell recruitment into the graft while maintaining each functional phenotype during vessel tissue maturation. The discussion of these significant research challenges constitutes the focus of this review.
Keywords: Extracellular matrix proteins, monocytes, natural biomaterials, progenitor cells, small caliber vessel, stem cells, synthetic biomaterials, vascular tissue engineering
Current Vascular Pharmacology
Title:Tissue Engineering a Small Diameter Vessel Substitute: Engineering Constructs with Select Biomaterials and Cells
Volume: 10 Issue: 3
Author(s): Joanne E. McBane, Soroor Sharifpoor, Rosalind S. Labow, Marc Ruel, Erik J. Suuronen and J. Paul Santerre
Affiliation:
Keywords: Extracellular matrix proteins, monocytes, natural biomaterials, progenitor cells, small caliber vessel, stem cells, synthetic biomaterials, vascular tissue engineering
Abstract: Cardiovascular disease (CVD) is a leading cause of death and hospitalization worldwide. The need for small caliber vessels (<6mm) to treat CVD patients has grown; however the availability of autologous vessels in cardiac and peripheral bypass candidates is limited. The search for an alternative vessel source is widespread with both natural and synthetic tissue engineered materials being investigated as scaffolds. Despite decades of exhaustive studies with decellularized extracellular matrices (ECM) and synthetic graft materials, the field remains in search of a commercially viable biomaterial construct substitute. While the previous materials have been assessed by evaluating their compatibility with fibroblasts, smooth muscle cells and endothelial cells, current materials are being conceived based on their interactions with stem cells, progenitor cells and monocytes, as the latter may hold the key to repair and regeneration. The graft’s ability to recruit and maintain these cells has become a major research focus. The successful tissue engineering of a small caliber vessel graft requires the use of optimal material chemistry and biological function to promote cell recruitment into the graft while maintaining each functional phenotype during vessel tissue maturation. The discussion of these significant research challenges constitutes the focus of this review.
Export Options
About this article
Cite this article as:
E. McBane Joanne, Sharifpoor Soroor, S. Labow Rosalind, Ruel Marc, J. Suuronen Erik and Paul Santerre J., Tissue Engineering a Small Diameter Vessel Substitute: Engineering Constructs with Select Biomaterials and Cells, Current Vascular Pharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157016112799959378
DOI https://dx.doi.org/10.2174/157016112799959378 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Relationship between SNP rs1764391 and Susceptibility, Risk Factors, Gene-environment Interactions of Acute Myocardial Infarction in Guangxi Han Chinese Population
Current Pharmaceutical Biotechnology Exosomes: Structure, Biogenesis, Types and Application in Diagnosis and Gene and Drug Delivery
Current Gene Therapy Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Impact of Hyperhomocyst(e)inemia on Endothelial Function
Vascular Disease Prevention (Discontinued) Obstructive Sleep Apnea and Cardiovascular Disease - A New Target for Treatment
Current Pharmaceutical Design Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Dyslipidemia as a Risk Factor for Erectile Dysfunction
Current Medicinal Chemistry Successfully Resuscitated Sudden Cardiac Death in a Young Homosexual Male with HIV Myocarditis
Current HIV Research Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery Lentinus edodes: A Macrofungus with Pharmacological Activities
Current Medicinal Chemistry The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Subject Index to Volume 1
Current Vascular Pharmacology Increased Content of Free Phenolic Compounds and Antioxidant Activity of Grape Pomace Cultivated with Three Different β-glucosidase Fungi Producers
Current Bioactive Compounds New Applications of Oleanolic Acid and its Derivatives as Cardioprotective Agents: A Review of their Therapeutic Perspectives
Current Pharmaceutical Design Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function
Current Drug Targets Anti-Inflammatory Responses of Resveratrol
Inflammation & Allergy - Drug Targets (Discontinued) Nanodiagnostic Attainments and Clinical Perspectives on C-Reactive Protein: Cardiovascular Disease Risks Assessment
Current Medicinal Chemistry Genetics of Cholesterol and Lipoprotein Metabolism
Recent Patents on Cardiovascular Drug Discovery Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery
Current Pharmaceutical Design